Last Read

ITN conducts a bi-monthly survey to its readers on a variety of topics, which is used to create the Last Read, a unique mix of radiology facts, figures and trends. This column offers a venue to get to know your colleagues, and see where you stand on different issues. Do you have a question you want us to ask? Contact Editorial Director Melinda Taschetta-Millane at [email protected].

As we come upon the calendar’s mid-year mark, it is time once again for the ITN team to begin its annual strategic planning for 2025. And we’d like to hear from you. By now, you have probably noticed the new content features ITN introduced this year, including the One on One … multimedia interview series, where we’ve held deep-dive discussions with respected industry professionals on impactful issues and initiatives.

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acquisition of the global rights of Life Molecular Imaging’s RM2, targeting the gastrin-releasing peptide receptor (GRP

Have a safe 4th of July from ITN in Chicago

The ITN team wishes you a safe and happy 4th of July!

July 3, 2024 — A new Harvey L. Neiman Health Policy Institute (HPI) study found that radiologists interpreted 72.1% of all imaging studies for Medicare fee-for-service beneficiaries in 2022, with the remaining 27.9% performed by other types of clinicians.

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to recognize health systems, imaging centers, hospitals, clinics and other facilities in which medical imaging technologists and radiation therapists demonstrate a culture of professionalism.  

July 3, 2024 — Proscia, a global leader in AI-enabled pathology solutions for precision medicine, has partnered with Nucleai, a leading spatial AI biomarker company that maps protein expression and cellular interactions within tissue samples to predict therapeutic outcomes.

July 3, 2024 — Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now